EGFR and non-small cell lung carcinoma: Although clonal mutations demonstrating resistance to targeted therapy may be of novel relevance to subsequent clonal neoantigen determination, work by Wu et al. [24] demonstrated response to CPI (nivolumab) in an advanced metastatic non-small cell lung cancer (NSCLC) patient who demonstrated progressive disease following acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) at the development of an EGFR exon 19 deletion mutation.